Emergent BioSolutions (EBS) Misses Q1 EPS by 65c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.23 --0%
EPS Growth %: -138.7%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -138.7%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.21, $0.65 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $156.1 million versus the consensus estimate of $205 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- Vital Farms pilots free-range eggs at Target stores under $5
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
